Rafarma Pharmaceuticals, producer of generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products, today reported the signing of a new exclusive production agreement with JSC F-Synthesis for the production of the anti-cancer drug Imatinib.
According to Pharmexpert, the leader in the Russian market for pharmaceutical business analysis, the market for Imatinib in Russia last year totaled slightly less than $200 million (USD). JSC F-Synthesis alone sold $30 million (USD) worth of Imatinib in 2012, putting the company in the top three national vendors of Imatinib.
In today’s press release, Rafarma told investors that this new contract will increase production volume while simultaneously reducing production costs, with increased sales volume and market share anticipated.
Used in the treatment of multiple cancers, Imatinib is important in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. The drug works as a form of targeted therapy — only cancer cells are killed through the drug’s action. In fact, Imatinib was one of the first cancer therapies to show the potential for such targeted action, and is often cited as a paradigm for research in cancer therapeutics.
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment